{"id":"symbicort-turbohaler-inhalation-powder","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Oral candidiasis"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Pharyngitis"},{"rate":"5-10%","effect":"Dysphonia"}]},"_chembl":{"chemblId":"CHEMBL2109052","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Budesonide works by reducing inflammation in the lungs, while formoterol helps to relax the airway muscles, making it easier to breathe. This combination helps to control symptoms of asthma and COPD, such as wheezing, coughing, and shortness of breath.","oneSentence":"Symbicort is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:02.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance and relief of asthma symptoms"},{"name":"Maintenance treatment of COPD"}]},"trialDetails":[{"nctId":"NCT01803555","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07-04","conditions":"Asthma","enrollment":605},{"nctId":"NCT02227394","phase":"PHASE2","title":"Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-08","conditions":"Asthma, Asthma Chronic, Asthma Bronchial","enrollment":20},{"nctId":"NCT03262012","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-08-09","conditions":"COPD","enrollment":416},{"nctId":"NCT02189304","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of PT010 in Healthy Subjects","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-06-01","conditions":"COPD","enrollment":59},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Symbicort"],"phase":"phase_3","status":"active","brandName":"Symbicort® Turbohaler® Inhalation Powder","genericName":"Symbicort® Turbohaler® Inhalation Powder","companyName":"Pearl Therapeutics, Inc.","companyId":"pearl-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Symbicort is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD). Used for Maintenance and relief of asthma symptoms, Maintenance treatment of COPD.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}